Cystic Fibrosis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Cystic Fibrosis – Pipeline Review, H1 2020’, provides an overview of the Cystic Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis

– The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects

– The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Molecular Therapeutics Inc

AbbVie Inc

Abeona Therapeutics Inc

Agile Sciences Inc

AGILeBiotics BV

Airway Therapeutics LLC

Alaxia SAS

AlgiPharma AS

Altavant Sciences Inc

Amgen Inc

Antabio SAS

Arch Biopartners Inc

Arcturus Therapeutics Ltd

Armata Pharmaceuticals Inc

Arrevus Inc

Arrowhead Pharmaceuticals Inc

AstraZeneca Plc

Atlantic Healthcare Plc

Avidin Ltd

BioAegis Therapeutics Inc

Biofilm Pharma

Biolytx Pharmaceuticals Corp

Boehringer Ingelheim International GmbH

Boston Pharmaceuticals Inc

Breathe Easy Therapeutics Ltd

BridgeBio Pharma Inc

Calista Therapeutics Inc

Calithera Biosciences Inc

Catabasis Pharmaceuticals Inc

Celtaxsys Inc

Chiesi Farmaceutici SpA

Chrysalis Pharma SAS

Cilian AG

Copernicus Therapeutics Inc

Corbus Pharmaceuticals Inc

CRISPR Therapeutics AG

CrowdOut Therapeutics

CSA Biotechnologies LLC

Cyclacel Pharmaceuticals Inc

Cyclenium Pharma Inc

Daiichi Sankyo Co Ltd

Destiny Pharma Plc

DiscoveryBiomed Inc

Druggability Technologies Holdings Ltd

Editas Medicine Inc

Eloxx Pharmaceuticals Inc

EmphyCorp Inc

EnBiotix Inc

Enterprise Therapeutics Ltd

Entrinsic Health Solutions, Inc.

Enzyvant Sciences Ltd

Errant Gene Therapeutics LLC

Evaxion Biotech ApS

Evotec SE

Exotect LLC

Galapagos NV

Galenus Therapeutics Inc

Generation Bio Corp

Genzyme Corp

Grupo Praxis Pharmaceutical SA

Helperby Therapeutics Group Ltd

Horizon Therapeutics PLC

Icagen Inc

Idorsia Pharmaceutical Ltd

Immun System IMS AB

Insmed Inc

Invion Ltd

Ionis Pharmaceuticals Inc

Kamada Ltd

Kither Biotech Srl

Kyorin Pharmaceutical Co Ltd

Lakewood-Amedex Inc

Lamellar Biomedical Ltd

Laurent Pharmaceuticals Inc

MannKind Corp

Mariposa Health Ltd

Microbion Corp

Mucokinetica Ltd

Nanogenics Ltd

Neupharma Srl

New Amsterdam Sciences Inc

Novabiotics Ltd

Novartis AG

Novoteris LLC

Omnispirant Ltd

Orphomed Inc

OrPro Therapeutics Inc

Oryn Therapeutics

Paranta Biosciences Ltd

Parion Sciences Inc

Pharmaero ApS

Pharmaxis Ltd

PhaseBio Pharmaceuticals Inc

Polyphor AG

Progenra Inc

ProQR Therapeutics NV

Protalix BioTherapeutics Inc

Proteostasis Therapeutics Inc

Pulmatrix Inc

Rare Partners Srl

Recode Therapeutics Inc

Renovion Inc

Riptide Bioscience Inc

Santhera Pharmaceuticals Holding AG

SciBac Inc

Sequoia Sciences Inc

Silurian Pharmaceuticals Inc

SolAeroMed Inc

Specific Biologics Inc

Spirovant Sciences Inc

Spyryx Biosciences Inc

Synedgen Inc

Synovo GmbH

Synspira LLC

Takeda Pharmaceutical Co Ltd

TGV-Inhalonix Inc

Therapeutic Systems Research Laboratories Inc

Translate Bio Inc

Trucode Gene Repair Inc

Vast Therapeutics Inc

Vectura Group Plc

Verona Pharma Plc

Vertex Pharmaceuticals Inc

Vironika LLC

Zambon Co SpA

Zata Pharmaceuticals Inc

Zikani Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Cystic Fibrosis - Overview

Cystic Fibrosis - Therapeutics Development

Cystic Fibrosis - Therapeutics Assessment

Cystic Fibrosis - Companies Involved in Therapeutics Development

Cystic Fibrosis - Drug Profiles

Cystic Fibrosis - Dormant Projects

Cystic Fibrosis - Discontinued Products

Cystic Fibrosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Cystic Fibrosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Cystic Fibrosis – Pipeline by 4D Molecular Therapeutics Inc, H1 2020

Cystic Fibrosis – Pipeline by AbbVie Inc, H1 2020

Cystic Fibrosis – Pipeline by Abeona Therapeutics Inc, H1 2020

Cystic Fibrosis – Pipeline by Agile Sciences Inc, H1 2020

Cystic Fibrosis – Pipeline by AGILeBiotics BV, H1 2020

Cystic Fibrosis – Pipeline by Airway Therapeutics LLC, H1 2020

Cystic Fibrosis – Dormant Projects, H1 2020

Cystic Fibrosis – Discontinued Products, H1 2020

Cystic Fibrosis – Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

List of Figures

Number of Products under Development for Cystic Fibrosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports